Logo image of CRBU

CARIBOU BIOSCIENCES INC (CRBU) Stock Fundamental Analysis

NASDAQ:CRBU - Nasdaq - US1420381089 - Common Stock - Currency: USD

1.31  -0.1 (-7.09%)

After market: 1.33 +0.02 (+1.53%)

Fundamental Rating

4

Overall CRBU gets a fundamental rating of 4 out of 10. We evaluated CRBU against 572 industry peers in the Biotechnology industry. While CRBU has a great health rating, there are worries on its profitability. While showing a medium growth rate, CRBU is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CRBU had negative earnings in the past year.
CRBU had a negative operating cash flow in the past year.
In the past 5 years CRBU always reported negative net income.
CRBU had a negative operating cash flow in each of the past 5 years.
CRBU Yearly Net Income VS EBIT VS OCF VS FCFCRBU Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -20M -40M -60M -80M -100M

1.2 Ratios

With a Return On Assets value of -43.02%, CRBU perfoms like the industry average, outperforming 52.40% of the companies in the same industry.
CRBU has a Return On Equity of -52.67%. This is in the better half of the industry: CRBU outperforms 63.94% of its industry peers.
Industry RankSector Rank
ROA -43.02%
ROE -52.67%
ROIC N/A
ROA(3y)-21.78%
ROA(5y)-39.7%
ROE(3y)-26%
ROE(5y)-63.54%
ROIC(3y)N/A
ROIC(5y)N/A
CRBU Yearly ROA, ROE, ROICCRBU Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CRBU so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CRBU Yearly Profit, Operating, Gross MarginsCRBU Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 -200 -400 -600

More info and screens

7

2. Health

2.1 Basic Checks

CRBU does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CRBU has been increased compared to 1 year ago.
There is no outstanding debt for CRBU. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CRBU Yearly Shares OutstandingCRBU Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 20M 40M 60M 80M
CRBU Yearly Total Debt VS Total AssetsCRBU Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 100M 200M 300M 400M

2.2 Solvency

Based on the Altman-Z score of -1.39, we must say that CRBU is in the distress zone and has some risk of bankruptcy.
CRBU has a Altman-Z score (-1.39) which is in line with its industry peers.
CRBU has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.39
ROIC/WACCN/A
WACC9.44%
CRBU Yearly LT Debt VS Equity VS FCFCRBU Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 100M -100M 200M 300M

2.3 Liquidity

CRBU has a Current Ratio of 7.38. This indicates that CRBU is financially healthy and has no problem in meeting its short term obligations.
CRBU has a better Current ratio (7.38) than 69.63% of its industry peers.
A Quick Ratio of 7.38 indicates that CRBU has no problem at all paying its short term obligations.
The Quick ratio of CRBU (7.38) is better than 69.63% of its industry peers.
Industry RankSector Rank
Current Ratio 7.38
Quick Ratio 7.38
CRBU Yearly Current Assets VS Current LiabilitesCRBU Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 100M 200M 300M

More info and screens

6

3. Growth

3.1 Past

CRBU shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -10.00%.
CRBU shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -66.84%.
Measured over the past years, CRBU shows a very strong growth in Revenue. The Revenue has been growing by 40.77% on average per year.
EPS 1Y (TTM)-10%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-216.67%
Revenue 1Y (TTM)-66.84%
Revenue growth 3Y40.77%
Revenue growth 5YN/A
Sales Q2Q%-91.45%

3.2 Future

Based on estimates for the next years, CRBU will show a quite strong growth in Earnings Per Share. The EPS will grow by 9.31% on average per year.
The Revenue is expected to grow by 49.97% on average over the next years. This is a very strong growth
EPS Next Y-16.64%
EPS Next 2Y-15.54%
EPS Next 3Y-13.81%
EPS Next 5Y9.31%
Revenue Next Year-70.59%
Revenue Next 2Y-46.09%
Revenue Next 3Y-6.88%
Revenue Next 5Y49.97%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CRBU Yearly Revenue VS EstimatesCRBU Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B
CRBU Yearly EPS VS EstimatesCRBU Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 10 15 20 25

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CRBU. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CRBU. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CRBU Price Earnings VS Forward Price EarningsCRBU Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CRBU Per share dataCRBU EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

CRBU's earnings are expected to decrease with -13.81% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-15.54%
EPS Next 3Y-13.81%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CRBU!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CARIBOU BIOSCIENCES INC

NASDAQ:CRBU (2/21/2025, 8:10:49 PM)

After market: 1.33 +0.02 (+1.53%)

1.31

-0.1 (-7.09%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2024-11-06/amc
Earnings (Next)N/A N/A
Inst Owners62.26%
Inst Owner Change-95.66%
Ins Owners4.74%
Ins Owner Change21.56%
Market Cap118.62M
Analysts82.67
Price Target13.52 (932.06%)
Short Float %10.98%
Short Ratio6.19
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)13.61%
Min EPS beat(2)10.1%
Max EPS beat(2)17.12%
EPS beat(4)2
Avg EPS beat(4)2.33%
Min EPS beat(4)-13.88%
Max EPS beat(4)17.12%
EPS beat(8)6
Avg EPS beat(8)12.49%
EPS beat(12)9
Avg EPS beat(12)9.67%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-12.08%
Min Revenue beat(2)-35.93%
Max Revenue beat(2)11.78%
Revenue beat(4)1
Avg Revenue beat(4)-16.61%
Min Revenue beat(4)-35.93%
Max Revenue beat(4)11.78%
Revenue beat(8)5
Avg Revenue beat(8)77.12%
Revenue beat(12)6
Avg Revenue beat(12)49.13%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)6%
PT rev (3m)-15.2%
EPS NQ rev (1m)0%
EPS NQ rev (3m)8.12%
EPS NY rev (1m)0%
EPS NY rev (3m)5.99%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-27.6%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-10.12%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 10.34
P/FCF N/A
P/OCF N/A
P/B 0.42
P/tB 0.42
EV/EBITDA N/A
EPS(TTM)-1.65
EYN/A
EPS(NY)-1.94
Fwd EYN/A
FCF(TTM)-1.44
FCFYN/A
OCF(TTM)-1.37
OCFYN/A
SpS0.13
BVpS3.11
TBVpS3.11
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -43.02%
ROE -52.67%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-21.78%
ROA(5y)-39.7%
ROE(3y)-26%
ROE(5y)-63.54%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 190.77%
Cap/Sales 57.82%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.38
Quick Ratio 7.38
Altman-Z -1.39
F-Score2
WACC9.44%
ROIC/WACCN/A
Cap/Depr(3y)314.64%
Cap/Depr(5y)219.36%
Cap/Sales(3y)34.11%
Cap/Sales(5y)24.02%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-10%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-216.67%
EPS Next Y-16.64%
EPS Next 2Y-15.54%
EPS Next 3Y-13.81%
EPS Next 5Y9.31%
Revenue 1Y (TTM)-66.84%
Revenue growth 3Y40.77%
Revenue growth 5YN/A
Sales Q2Q%-91.45%
Revenue Next Year-70.59%
Revenue Next 2Y-46.09%
Revenue Next 3Y-6.88%
Revenue Next 5Y49.97%
EBIT growth 1Y-51.27%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-43.52%
EBIT Next 3Y-15.75%
EBIT Next 5YN/A
FCF growth 1Y-41.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-42.15%
OCF growth 3YN/A
OCF growth 5YN/A